International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury
February 13 2019 - 8:30AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2019/2/13/edaxcInternational_Stemcell_-_Capture.PNG)
International
Stem Cell Corporation Publishes Successful Results in Traumatic
Brain Injury
CARLSBAD, Calif. --
February 13, 2019 -- InvestorsHub NewsWire -- International
Stem Cell Corporation (OTCQB:ISCO)
(www.internationalstemcell.com)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company developing novel stem cell-based therapies
and biomedical products, announced today that the results of the
Company’s preclinical studies in traumatic brain injury (TBI) have
been published in Theranostics, a prestigious peer-reviewed medical
journal. The publication, titled, “Human parthenogenetic neural
stem cell grafts promote multiple regenerative processes in a
traumatic brain injury model,” demonstrated that the clinical-grade
neural stem cells used in our Parkinson’s disease clinical trial,
ISC-hpNSC®, significantly improve TBI-associated motor,
neurological, and cognitive deficits without any safety issues. The
paper is available on the Company’s
website.
The article details
ISCO’s preclinical studies in TBI conducted by world-renowned Dr.
Cesar Borlongan, Director and Distinguished Professor of the Center
of Excellence for Aging and Brain Repair at the University of South
Florida Morsani College of
Medicine.
“ISCO’s human
parthenogenetic neural stem cells may have a strong therapeutic
value for patients suffering from traumatic brain injury (TBI).
Transplantation of the neural stem cells in the brain were able to
restore motor function, learning, and
memorizationin the TBI rodent
model. Animals receiving the cells had increased neuronal survival
and reduced inflammation compared to the untreated group,”
commented Prof. Borlongan.
Rodents injected with
moderate and high doses of ISC-hpNSC® significantly improved motor
function, neurologic function, and cognition compared to the
control animals receiving no treatment. Also, histological analysis
demonstrated increased expression of neural and myelination markers
and decreased reactive gliosis and inflammation in the brains of
animals receiving moderate and high doses of ISC-hpNSC® compared to
the untreated group.
“The results of these
studies add to the validation of ISC-hpNSC® as a potential
therapeutic platform to treat a broad spectrum of neurological
disorders. There is currently no approved treatment for TBI and it
represents a significant unmet medical need with millions affected
annually. For ISCO this may open new opportunities with large
market potential,” commented Russell Kern, PhD, ISCO's EVP, Chief
Scientific Officer.
According to the World
Health Organization, the global incidence for TBI is approximately
10 million people annually.TBI
is also a leading cause of death and disability in the United
States, contributing to approximately 30% of all injury
deaths.
About International Stem Cell
Corporation
International Stem
Cell Corporation (ISCO) is focused on the therapeutic applications
of human parthenogenetic stem cells (hpSCs) and the development and
commercialization of cell-based research and cosmetic products.
ISCO's core technology, parthenogenesis, results in the creation of
pluripotent human stem cells from unfertilized oocytes (eggs).
hpSCs avoid ethical issues associated with the use or destruction
of viable human embryos. ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of
differing genders, ages and racial background with minimal immune
rejection after transplantation. hpSCs offer the potential to
create the first true stem cell bank, UniStemCell™. ISCO also
produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology (www.lifelinecelltech.com), and stem
cell-based skin care products through its subsidiary Lifeline Skin
Care (www.lifelineskincare.com). More information is
available at www.internationalstemcell.com.
To subscribe to
receive ongoing corporate communications, please click on the
following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook
page or follow us on Twitter for company updates and industry
related news, visit:
www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor
statement
Statements pertaining
to anticipated developments, clinical studies expectations
(including plans for future clinical trials), progress of research
and development, and other opportunities for the Company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, regulatory approvals, need and ability to
obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights.
Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated
together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the Company's Securities and Exchange Commission filings.
The Company disclaims any intent or obligation to update
forward-looking statements.
Contacts:
International Stem Cell
Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: ir@intlstemcell.com
Or
Edison
Advisors
Tirth Patel
Vice President, Investor Relations
(646) 653-7035
tpatel@edisongroup.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jul 2024 to Aug 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Aug 2023 to Aug 2024